|Mr. Jean-Christophe Tellier||Chief Exec. Officer and Exec. Director||3.07M||N/A||58|
|Mr. Detlef Thielgen||Chief Financial Officer and Exec. VP||N/A||N/A||57|
|Dr. Ismail Kola Ph.D.||Chief Scientific Officer & New Medicines Patient Value Unit Head||N/A||N/A||60|
|Ms. Anna S. Richo||Exec. VP and Gen. Counsel||N/A||N/A||57|
|Dr. Bharat Tewarie||Chief Marketing Officer and Exec. VP||N/A||N/A||56|
UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. Its core products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohns disease, psoriatic arthritis, and rheumatoid arthritis; Keppra, Vimpat, and Briviact for epilepsy; and Neupro for Parkinsons disease and restless legs syndrome. The company also offers Zyrtec and Xyzal for allergy; Venlafaxine ER for depressive and anxiety disorders; Nootropil for cognitive disorders; and Xyrem for narcolepsy. Its product pipeline includes UCB0942 for highly drug resistant epilepsy; dapirolizumab pegol for systemic lupus erythematosus; bimekizumab for various indications; bimekizumab, add-on to Cimzia for rheumatoid arthritis; seletalisib for Sjögrens syndrome; UCB7665 for immune thrombocytopenia; UCB1332 for Parkinsons disease; UCB4144/VR942 for asthma; UCB6673 for immunological diseases; UCB3491 for epilepsy; and UCB7858 for auto-inflammatory diseases. UCB SA was founded in 1928 and is headquartered in Brussels, Belgium.
UCB SA’s ISS Governance QualityScore as of August 1, 2017 is 4. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 4; Compensation: 5.